Share Price | 908 Devices, Inc. Stock Analysis & Recommendation

Q: How big is 908 Devices, Inc.?

Market Cap: As of Jun 18, 908 Devices, Inc. has a market capitalization of 263.58 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 61.42 million, while the sum of Net Profit is -71.14 million.Balance Sheet Snapshot: As of Dec 24, the Shareholder's Funds amount to 114.59 million, and the Total Assets are valued at 159.48 million.

Q: What does 908 Devices, Inc. do?

Overview: 908 Devices, Inc. operates within the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 12 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market cap: USD 263.58 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.77 Return on Equity: -16.05% Price to Book: 1.65Contact Details: Registrar Address: Not available.

Q: Should I buy, sell or hold 908 Devices, Inc.?

Based on the current financial performance of 908 Devices, Inc., it would be advisable to consider selling your shares. The company has reported a significant decline in net sales, down 21% to USD 11.78 million, and its operating cash flow is at a concerning low of USD -35.91 million. Additionally, the return on capital employed (ROCE) is negative at -44.97%, indicating inefficiencies in generating returns from its capital.Moreover, the stock is trading at a risky valuation compared to its historical averages, and despite a 0% return over the past year, profits have only increased by 26.1%. Given these factors, holding or buying more shares could expose you to further risk. It may be prudent to reassess your investment in light of these negative indicators.

Q: Is 908 Devices, Inc. technically bullish or bearish?

As of 29 July 2025, the technical trend for 908 Devices, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and bullish Bollinger Bands on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, indicating some caution. The stock has performed significantly well year-to-date with a return of 210.0%, compared to the S&P 500's 12.22%, and has also outperformed the index over the past year with an 84.82% return versus 17.14%. Overall, while there are mixed signals, the strength of the bullish indicators suggests a positive outlook.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

552.74 k

Shareholding (Dec 2025)

FII

6.66%

Held by 46 FIIs

DII

55.78%

Held by 39 DIIs

Promoter

2.23%

How big is 908 Devices, Inc.?

22-Jun-2025

As of Jun 18, 908 Devices, Inc. has a market capitalization of 263.58 million, with net sales of 61.42 million and a net profit of -71.14 million over the latest four quarters. Shareholder's funds are 114.59 million, and total assets are valued at 159.48 million as of Dec 24.

View full answer

What does 908 Devices, Inc. do?

22-Jun-2025

908 Devices, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $12 million and a net loss of $10 million as of March 2025, with a market cap of $263.58 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -16.05%.

View full answer

Should I buy, sell or hold 908 Devices, Inc.?

22-Jun-2025

Is 908 Devices, Inc. technically bullish or bearish?

20-Sep-2025

As of July 29, 2025, 908 Devices, Inc. shows a mildly bullish trend with strong year-to-date performance of 210%, despite some caution from weekly indicators.

View full answer

Compare 908 Devices, Inc. with Similar Stocks

Axogen, Inc.Standard BioTools, Inc.Allurion Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of 24.1%, the company declared Very Positive results in Sep 25

OPERATING CASH FLOW(Y) Highest at USD -27.24 MM
NET PROFIT(HY) Higher at USD -2.12 MM
RAW MATERIAL COST(Y) Fallen by -2.22% (YoY)

Risky -

High Institutional Holdings at 91.74%

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 228 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.82

Return on Equity

-14.48%

Price to Book

1.67

Revenue and Profits:

Net Sales:

17 Million

(Quarterly Results - Dec 2025)

Net Profit:

4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

12.94%

6 Months

-19.07%

1 Year

34.88%

2 Years

-8.81%

3 Years

-19.92%

4 Years

-69.08%

5 Years

-87.02%

908 Devices, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

14.31%

EBIT Growth (5y)

-256.34%

EBIT to Interest (avg)

-28.42

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.77

Sales to Capital Employed (avg)

0.36

Tax Ratio

0.30%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

91.74%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.67

EV to EBIT

-4.57

EV to EBITDA

-5.63

EV to Capital Employed

4.69

EV to Sales

2.01

PEG Ratio

Dividend Yield

ROCE (Latest)

-102.73%

ROE (Latest)

-14.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (35.33%)

Foreign Institutions

Held by 46 Foreign Institutions (6.66%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 24.29% vs 7.69% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 130.20% vs -15.50% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "17.40",
          "val2": "14.00",
          "chgp": "24.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-4.40",
          "chgp": "54.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "6.30",
          "val2": "-10.80",
          "chgp": "158.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.50",
          "val2": "-14.90",
          "chgp": "130.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-182.20%",
          "val2": "-393.90%",
          "chgp": "21.17%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 17.82% vs -4.98% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 37.29% vs -45.88% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "56.20",
          "val2": "47.70",
          "chgp": "17.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.70",
          "val2": "-25.30",
          "chgp": "22.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.20",
          "val2": "-27.40",
          "chgp": "44.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-33.30",
          "val2": "-53.10",
          "chgp": "37.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-430.30%",
          "val2": "-627.30%",
          "chgp": "19.70%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

17.40

14.00

24.29%

Operating Profit (PBDIT) excl Other Income

-2.00

-4.40

54.55%

Interest

0.00

Exceptional Items

6.30

-10.80

158.33%

Consolidate Net Profit

4.50

-14.90

130.20%

Operating Profit Margin (Excl OI)

-182.20%

-393.90%

21.17%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 24.29% vs 7.69% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 130.20% vs -15.50% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

56.20

47.70

17.82%

Operating Profit (PBDIT) excl Other Income

-19.70

-25.30

22.13%

Interest

0.00

Exceptional Items

-15.20

-27.40

44.53%

Consolidate Net Profit

-33.30

-53.10

37.29%

Operating Profit Margin (Excl OI)

-430.30%

-627.30%

19.70%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 17.82% vs -4.98% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 37.29% vs -45.88% in Dec 2024

All Annual Results

Company CV

About 908 Devices, Inc.

908 Devices, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available